Abstract | BACKGROUND: METHODS AND RESULTS: CRP, IL-6, MMP-9, and WBC were analyzed from stored frozen serum samples obtained from patients with type 2 diabetes who completed a 26-week randomized, double-blind, placebo-controlled study. After 26 weeks of rosiglitazone treatment, the percentage reductions in mean CRP, MMP-9, and WBC levels were statistically significant compared with baseline and placebo (P<0.01). The percentage reduction in mean IL-6 was small and similar in the rosiglitazone and placebo groups. The change in each inflammatory marker from baseline to week 26 was significantly correlated (P<0.05) with each of the other markers, as well as with the homeostasis model assessment estimate of insulin resistance. CONCLUSIONS:
Rosiglitazone reduces serum levels of MMP-9 and the proinflammatory marker CRP in patients with type 2 diabetes, which indicates potentially beneficial effects on overall cardiovascular risk.
|
Authors | Steven M Haffner, Andrew S Greenberg, Wayde M Weston, Hongzi Chen, Ken Williams, Martin I Freed |
Journal | Circulation
(Circulation)
Vol. 106
Issue 6
Pg. 679-84
(Aug 06 2002)
ISSN: 1524-4539 [Electronic] United States |
PMID | 12163427
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers
- Interleukin-6
- Receptors, Cytoplasmic and Nuclear
- Thiazoles
- Thiazolidinediones
- Transcription Factors
- Rosiglitazone
- C-Reactive Protein
- Matrix Metalloproteinase 9
|
Topics |
- Biomarkers
(blood)
- Body Weight
(drug effects)
- C-Reactive Protein
(analysis)
- Cardiovascular Diseases
(etiology)
- Diabetes Mellitus, Type 2
(blood, complications, drug therapy)
- Diabetic Angiopathies
(etiology)
- Double-Blind Method
- Female
- Humans
- Interleukin-6
(blood)
- Leukocyte Count
- Male
- Matrix Metalloproteinase 9
(blood)
- Middle Aged
- Receptors, Cytoplasmic and Nuclear
(agonists)
- Risk Factors
- Rosiglitazone
- Thiazoles
(therapeutic use)
- Thiazolidinediones
- Transcription Factors
(agonists)
|